These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26097901)

  • 1. Daclatasvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Rizza SA
    Drugs Today (Barc); 2015 May; 51(5):277-88. PubMed ID: 26097901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
    Herbst DA; Reddy KR
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1337-46. PubMed ID: 23931586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
    McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
    Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.
    McCormack PL
    Drugs; 2015 Apr; 75(5):515-24. PubMed ID: 25721433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
    Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
    J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
    Smith MA; Regal RE; Mohammad RA
    Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
    Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
    Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
    Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
    J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclatasvir: potential role in hepatitis C.
    Lee C
    Drug Des Devel Ther; 2013; 7():1223-33. PubMed ID: 24204123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
    Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
    J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
    Zeuli JD; Adie SK; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Hong CM; Liu CJ; Yeh SH; Chen PJ
    J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
    Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
    Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
    N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
    Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
    Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
    J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
    Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
    Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.